drugset / Trial / NCT02233751

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

NCT02233751

Phase 1 Completed 12 enrolled Antares Pharma Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluation of pharmacokinetics of subcutaneous testosterone enanthate

Timeline

Start
2014-09
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Enanthate Small molecule 50 mg Subcutaneous
Subject Testosterone Enanthate Small molecule 200 mg Subcutaneous

Indications